The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 ...

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

FDA officials have warned the American public to not eat, sell or serve cucumbers grown and distributed by two Florida ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...